SEC Form 4 · accession 0001209191-15-027295
EAGLE PHARMACEUTICALS, INC. · EGRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David E Riggs
Officer — Chief Financial Officer
Period of report
Mar 13, 2015
Accepted (ET)
Mar 17, 2015 · 8:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827871
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option (right to buy)F1 | $46.09 | Mar 13, 2015 | A | 56,286 | A | — | Mar 12, 2025 | Common Stock | 56,286 | 56,286 | D |
Explanation of responses
- F1The option vests over a period of four years, with 25% of the shares underlying the option vesting on March 13, 2016, the first anniversary of the date of grant, and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.